SCHEMBL19983432

SCHEMBL19983432

CC(CNCc1ccccc1)C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)C(O)C1O

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 4/20 0.73
AHCY P23526 1/20 0.60
ATM Q13315 1/20 0.59
NSD2 O96028 2/20 0.58
DOT1L Q8TEK3 5/20 0.58
EHMT2 Q96KQ7 4/20 0.57
ADORA1 P30542 3/20 0.57
ADORA3 P0DMS8 2/20 0.57
DPP4 P27487 1/20 0.57
MEN1 O00255 1/20 0.57
SLC28A1 O00337 1/20 0.57
MAP3K7 O43318 1/20 0.57
SLC28A2 O43868 1/20 0.57
GAPDH P04406 1/20 0.57
MAPK1 P28482 1/20 0.57
ADORA2A P29274 1/20 0.57
ADORA2B P29275 1/20 0.57
STAT6 P42226 1/20 0.57
PI4KA P42356 1/20 0.57
KMT2A Q03164 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19983463 1.00 CARM1 (0.73) CARM1AHCYATMNSD2DOT1L
SCHEMBL6900816 0.86 ATM (0.76) CARM1AHCYATMDOT1LADORA1
SCHEMBL14906024 0.84 CARM1 (1.00) CARM1NSD2DOT1LEHMT2KMT2A
SCHEMBL19983489 0.84 CARM1 (1.00) CARM1NSD2DOT1LEHMT2KMT2A
SCHEMBL16156831 0.84 CARM1 (1.00) CARM1NSD2DOT1LEHMT2KMT2A
SCHEMBL19983490 0.84 CARM1 (0.82) CARM1AHCYNSD2DOT1LEHMT2
SCHEMBL16154100 0.82 CARM1 (0.75) CARM1AHCYNSD2DOT1LEHMT2
SCHEMBL26453664 0.82 CARM1 (0.76) CARM1AHCYNSD2DOT1LEHMT2
SCHEMBL19111312 0.81 AMD1 (0.67) CARM1AHCYATMDOT1LKMT2A
SCHEMBL19760477 0.81 DOT1L (0.74) CARM1AHCYNSD2DOT1LEHMT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12043645-B2 Adenosine analogs as methyltransferase inhibitors for treating cancer MEMORIAL SLOAN-KETTERING CANCER CENTER (US) 2024-07-23 US disclosed
US-20230135822-A1 ADENOSINE ANALOGS AS METHYLTRANSFERASE INHIBITORS FOR TREATING CANCER MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2023-05-04 US disclosed
US-20210017216-A1 ADENOSINE ANALOGS AS METHYLTRANSFERASE INHIBITORS FOR TREATING CANCER MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2021-01-21 US disclosed
US-10730903-B2 Adenosine analogs as methyltransferase inhibitors for treating cancer MEMORIAL SLOAN-KETTERING CANCER CENTER (US) 2020-08-04 US disclosed
US-20190276488-A1 ADENOSINE ANALOGS AS METHYLTRANSFERASE INHIBITORS FOR TREATING CANCER MEMORIAL SLOAN-KETTERING CANCER CENTER (US) 2019-09-12 US disclosed
WO-2018053313-A1 ADENOSINE ANALOGS AS METHYLTRANSFERASE INHIBITORS FOR TREATING CANCER MEMORIAL SLOAN-KETTERING CANCER CENTER (US) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210017216-A1 ADENOSINE ANALOGS AS METHYLTRANSFERASE INHIBITORS FOR TREATING CANCER DIMT1, TPMT, MTAP CARM1 62/4885AHCY 31/4885ATM 599/4885
US-20190276488-A1 ADENOSINE ANALOGS AS METHYLTRANSFERASE INHIBITORS FOR TREATING CANCER DIMT1, TPMT, MTAP CARM1 62/4885AHCY 31/4885ATM 599/4885
US-12043645-B2 Adenosine analogs as methyltransferase inhibitors for treating cancer DIMT1, TPMT, MTAP CARM1 62/4885AHCY 31/4885ATM 599/4885
US-20230135822-A1 ADENOSINE ANALOGS AS METHYLTRANSFERASE INHIBITORS FOR TREATING CANCER DIMT1, TPMT, MTAP CARM1 62/4885AHCY 31/4885ATM 599/4885
US-10730903-B2 Adenosine analogs as methyltransferase inhibitors for treating cancer DIMT1, TPMT, MTAP CARM1 62/4885AHCY 31/4885ATM 599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.